Last reviewed · How we verify
NCT06044077
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Phase 3 trial testing 23-valent pneumococcal polysaccharide vaccine in Pneumococcal Disease in 1,920 participants. Currently enrolling.
8 March 2024
Quick facts
| Lead sponsor | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,920 |
| Start date | 8 September 2023 |
| Primary completion | 8 March 2024 |
| Estimated completion | 31 July 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- 23-valent pneumococcal polysaccharide vaccine — full drug profile →
- control pneumococcal polysaccharide vaccine — full drug profile →
Conditions studied
- Pneumococcal Disease — all drugs for Pneumococcal Disease →
Sponsor
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. — full company profile →
Who can join
2 and older, any sex, with Pneumococcal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06044077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 23-valent pneumococcal polysaccharide vaccine
Trials testing the same drug.
- NCT07071701 — A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population · completed
- NCT04551248 — Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults. · unknown
- NCT04953325 — Immunogenicity and Safety of an Inactivated COVID-19 Vaccine · Phase 4 · completed
- NCT04701788 — A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly · Phase 4 · completed
- NCT04700618 — A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old · Phase 4 · completed
Other recruiting trials for Pneumococcal Disease
Currently open trials in the same condition.
- NCT07023081 — A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant · Phase 1 · active not recruiting
- NCT06622109 — A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months · active not recruiting
- NCT06524414 — A Study to Learn About How a New Pneumococcal Vaccine Works in Infants · Phase 2 · active not recruiting
- NCT06182124 — A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06044077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06044077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing